source
- BioNTech spends $205 million to buy Scholar Rock’s FDA priority-review voucher as J&J scales back in NorwayBioNTech announced it has purchased an FDA priority review voucher from Scholar Rock for $205 million. The voucher, which can be used to accelerate the regulatory review of a future drug, was origi…
- Senate debate looms over Heidi Overton’s potential FDA nominationThe article raises the question of whether Heidi Overton will be nominated to head the FDA and how the Senate might respond. It notes that a committee chair typically schedules a confirmation vote…